Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Merck's ADC-Keytruda Combo Shows Promise in First-Line Lung Cancer Treatment

Merck's ADC-Keytruda Combo Shows Promise in First-Line Lung Cancer Treatment

Merck & Co. and its partner Kelun-Biotech have reported a significant breakthrough in the treatment of non-small cell lung cancer (NSCLC), as their antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) combined with Keytruda demonstrated superior efficacy in a phase 3 trial.

NoahAI News11/25/2025
AI-Powered Women's Health Startup Millie Launches Maia Agent, Prepares for AI-Forward Future

AI-Powered Women's Health Startup Millie Launches Maia Agent, Prepares for AI-Forward Future

Women's health startup Millie has taken a significant step towards revolutionizing maternal care with the launch of its AI agent, Maia. This development comes as part of the company's broader strategy to integrate artificial intelligence into its healthcare services, positioning itself at the forefront of the AI revolution in women's health.

NoahAI News11/25/2025
Sarepta's RNA Therapy for DM1 Progresses, Triggering $200M Milestone Payment to Arrowhead

Sarepta's RNA Therapy for DM1 Progresses, Triggering $200M Milestone Payment to Arrowhead

Sarepta Therapeutics has announced positive developments in its phase 1/2 trial for SRP-1003, a small interfering RNA (siRNA) therapeutic targeting type 1 myotonic dystrophy (DM1). The progress has resulted in a significant milestone payment to partner Arrowhead Pharmaceuticals and has been met with enthusiasm from industry analysts.

NoahAI News11/25/2025
Optum Rx Expands Prior Authorization Reduction Initiatives, Surpassing Initial Goals

Optum Rx Expands Prior Authorization Reduction Initiatives, Surpassing Initial Goals

Optum Rx, the pharmacy benefit management arm of UnitedHealth Group, has announced significant expansions to its prior authorization reduction initiatives, exceeding its original targets set earlier this year. The company will implement these changes starting January 1, 2026, marking a substantial shift in how medication approvals are handled for millions of patients.

NoahAI News11/25/2025
J&J MedTech Expands Stroke R&D Programs in Ireland, Reinforcing Global Neurovascular Innovation

J&J MedTech Expands Stroke R&D Programs in Ireland, Reinforcing Global Neurovascular Innovation

Johnson & Johnson MedTech is bolstering its stroke-focused research and development efforts in Ireland, marking a significant expansion of its neurovascular capabilities in the region. This move builds upon previous investments and follows the completion of a new innovation center in Galway earlier this year.

NoahAI News11/25/2025
Bayer's Asundexian Shows Promise in Phase III Stroke Prevention Study

Bayer's Asundexian Shows Promise in Phase III Stroke Prevention Study

Bayer's investigational Factor XIa inhibitor, asundexian, has demonstrated significant efficacy in stroke prevention, according to recent Phase III clinical trial results. This development marks a potential turnaround for the drug, which previously faced setbacks in atrial fibrillation studies.

NoahAI News11/24/2025
J&J's Alzheimer's Ambitions Suffer Setback as Anti-Tau Antibody Fails Phase 2 Trial

J&J's Alzheimer's Ambitions Suffer Setback as Anti-Tau Antibody Fails Phase 2 Trial

Johnson & Johnson's aspirations to develop a blockbuster Alzheimer's disease treatment have been dealt a significant blow following the failure of its anti-tau antibody, posdinemab, in a phase 2 clinical trial. The company announced that the drug failed to significantly slow clinical decline in patients with early Alzheimer's, leading to the termination of the study.

NoahAI News11/24/2025
Solventum Expands Wound Care Portfolio with $850M Acera Surgical Acquisition

Solventum Expands Wound Care Portfolio with $850M Acera Surgical Acquisition

Solventum, the healthcare company spun out from 3M in 2024, has announced its first major acquisition since becoming an independent entity. The company will acquire wound care specialist Acera Surgical for up to $850 million, marking a significant expansion of its advanced wound care portfolio.

NoahAI News11/24/2025
Bayer's Asundexian Succeeds in Phase 3 Stroke Prevention Trial, Reviving FXIa Inhibitor Class

Bayer's Asundexian Succeeds in Phase 3 Stroke Prevention Trial, Reviving FXIa Inhibitor Class

Bayer AG has announced a significant breakthrough in the development of its oral Factor XIa (FXIa) inhibitor, asundexian, potentially revitalizing a drug class that has faced recent setbacks. The phase 3 trial for secondary stroke prevention met its primary efficacy and safety endpoints, marking a crucial milestone for the company and the broader pharmaceutical industry.

NoahAI News11/24/2025
Cell and Gene Therapy Advances Promise Transformative Treatments Amidst Regulatory Evolution

Cell and Gene Therapy Advances Promise Transformative Treatments Amidst Regulatory Evolution

The cell and gene therapy (CGT) sector is experiencing a resurgence of optimism, driven by clinical breakthroughs, regulatory adaptations, and growing market potential. Despite recent challenges, including trial suspensions and increased scrutiny, the field is making significant strides in addressing unmet medical needs and reshaping the future of healthcare.

NoahAI News11/24/2025
CRISPR and Omics: New Frontiers in Alzheimer's Research

CRISPR and Omics: New Frontiers in Alzheimer's Research

Groundbreaking developments in gene editing and omics technologies are reshaping the landscape of Alzheimer's disease (AD) research, offering new hope for diagnosis, treatment, and prevention. Recent studies have highlighted the potential of CRISPR technology to modify genetic risk factors, while advancements in omics are providing unprecedented insights into disease mechanisms.

NoahAI News11/24/2025
FDA Investigates Patient Death Linked to Takeda's Enzyme Replacement Therapy Adzynma

FDA Investigates Patient Death Linked to Takeda's Enzyme Replacement Therapy Adzynma

The U.S. Food and Drug Administration (FDA) has launched an investigation into Takeda's recombinant protein medication Adzynma following reports of adverse events, including one patient death. The probe focuses on the development of neutralizing antibodies in patients treated with the enzyme replacement therapy for congenital thrombotic thrombocytopenic purpura (cTTP).

NoahAI News11/22/2025
«1...141516...67»